特发性全面性癫痫女性从丙戊酸换用其他药物后癫痫复发的预测因素
这项多中心回顾性研究纳入16个癫痫中心的426例育龄期特发性全面性癫痫女性,分析从丙戊酸换用其他抗癫痫发作药物后12个月和24个月全面强直-阵挛发作加重或复发的预测因素,并比较左乙拉西坦与拉莫三嗪的疗效。结果显示换药后12个月和24个月分别有105例(24.6%)和139例(32.6%)出现发作加重或复发,左乙拉西坦较拉莫三嗪与全面强直-阵挛发作加重或复发风险降低相关(校正HR 0.59,95%CI 0.40-0.87,p=0.008)。
要点
- 换药后12个月和24个月全面强直-阵挛发作加重或复发率分别为24.6%和32.6%。
- 月经期发作加重、换药时丙戊酸剂量较高、多种发作类型和换药前全面强直-阵挛发作控制时间较短是12个月复发的独立预测因素。
- 在换用左乙拉西坦或拉莫三嗪的337例女性中,左乙拉西坦较拉莫三嗪与24个月随访期间全面强直-阵挛发作加重或复发风险降低相关(校正HR 0.59,95%CI 0.40-0.87,p=0.008)。
核心结论
- 在从丙戊酸换用其他抗癫痫发作药物的特发性全面性癫痫育龄期女性中,左乙拉西坦较拉莫三嗪与全面强直-阵挛发作加重或复发风险降低相关(校正HR 0.59,95%CI 0.40-0.87,p=0.008)。
研究设计与样本
- 多中心回顾性研究,纳入来自16个癫痫中心的426例育龄期特发性全面性癫痫女性。
- 换药时中位年龄24(19-30)岁,中位丙戊酸剂量750(500-1,000)mg/d。
- 换药最常见原因为致畸担忧249例(58.6%),最常用替代药物为左乙拉西坦197例(46.2%),其次为拉莫三嗪140例(32.9%)。
- 通过逆概率治疗加权(IPTW)Cox回归分析比较左乙拉西坦与拉莫三嗪作为丙戊酸替代药物的疗效。
主要发现
- 全面强直-阵挛发作加重或复发在12个月和24个月分别发生于105例(24.6%)和139例(32.6%)女性。
- 混合多变量逻辑回归分析显示,月经期发作加重、换药时丙戊酸剂量较高、多种发作类型和换药前全面强直-阵挛发作控制时间较短是12个月全面强直-阵挛发作复发或加重的独立预测因素。
- 经过16个独立队列的内部-外部验证,模型曲线下面积为0.71(95%CI 0.64-0.77)。
- 在换用左乙拉西坦或拉莫三嗪的337例女性亚组中,IPTW Cox回归分析显示,24个月随访期间左乙拉西坦较拉莫三嗪与全面强直-阵挛发作加重或复发风险降低相关(校正HR 0.59,95%CI 0.40-0.87,p=0.008)。
关键数值与推荐
- 本研究提供III级证据:对于从丙戊酸换药的特发性全面性癫痫女性,左乙拉西坦较拉莫三嗪与全面强直-阵挛发作加重或复发风险降低相关(校正HR 0.59,95%CI 0.40-0.87,p=0.008)。
临床怎么用
- 作者认为,研究结果对优化育龄期特发性全面性癫痫女性的咨询和治疗选择具有实际意义,可能有助于临床医生在这一特殊患者群体中做出知情治疗决策。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: To investigate the predictors of seizure recurrence in women of childbearing age with idiopathic generalized epilepsy (IGE) who switched from valproate (VPA) to alternative antiseizure medications (ASMs) and compare the effectiveness of levetiracetam (LEV) and lamotrigine (LTG) as VPA alternatives after switch. METHODS: This multicenter retrospective study included women of childbearing age diagnosed with IGE from 16 epilepsy centers. Study outcomes included worsening or recurrence of generalized tonic-clonic seizure (GTCS) at 12 months and 24 months after the switch from VPA to an alternative ASM. The comparative effectiveness of LEV and LTG as alternative ASM following VPA discontinuation was assessed through inverse probability treatment-weighted (IPTW) Cox regression analysis. RESULTS: We included 426 women with IGE, with a median (interquartile range) age at VPA switch of 24 (19-30) years and a median VPA dosage of 750 (500-1,000) mg/d. The most common reason for VPA switch was teratogenicity concern in 249 women (58.6%), and the most common ASM used in place of VPA was LEV in 197 (46.2%) cases, followed by LTG in 140 (32.9%). GTCS worsening/recurrence occurred in 105 (24.6%) and 139 (32.6%) women at 12 and 24 months, respectively. Catamenial worsening of seizures, higher VPA dosage during switch, multiple seizure types, and shorter duration of GTCS freedom before switch were independent predictors of GTCS recurrence or worsening at 12 months according to mixed multivariable logistic regression analysis. After internal-external validation through 16 independent cohorts, the model showed an area under the curve of 0.71 (95% CI 0.64-0.77). In the subgroup of 337 women who switched to LEV or LTG, IPTW Cox regression analysis showed that LEV was associated with a reduced risk of GTCS worsening or recurrence compared with LTG (adjusted hazard ratio 0.59, 95% CI 0.40-0.87, p = 0.008) during the 24-month follow-up. DISCUSSION: Our findings can have practical implications for optimizing counselling and treatment choices in women of childbearing age with IGE and may help clinicians in making informed treatment decisions in this special population of patients. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that for women with IGE switching from VPA, LEV was associated with a reduced risk of GTCS worsening or recurrence compared with LTG.
引用
- Cerulli Irelli E, Cocchi E, Morano A, et al. Predictors of Seizure Recurrence in Women With Idiopathic Generalized Epilepsy Who Switch From Valproate to Another Medication. Neurology. 2024. PMID: 38569127. doi:10.1212/WNL.0000000000209222
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。